Procept BioRobotics announces long-term, real-world data on Aquablation

PROCEPT BioRobotics announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia at both academic and commercial settings. The results were presented this past weekend at the American Urological Association Annual Meeting in San Antonio, Texas. Icahn School of Medicine at Mount Sinai – 4-Year Outcomes: Key results: Mean prostate volume decreased from 108.3 mL to 66.2 mL; International Prostate Symptom Score improved from 24.2 at baseline to 7.1 at 4 years; Peak urinary flow rate increased nearly 3-fold from 6.1 mL/sec to 17.1 mL/sec; Antegrade ejaculation was preserved for 99% of men; Surgical retreatment occurred in 1.8% patients. Potomac Urology – Aquablation Case Series of 812 Consecutive Men with LUTS due to BPH: Key results: Mean age, IPSS, Qmax and prostate volume were 69 +/- 8, 21 +/- 7, 11 +/- 6, and 77 ml, respectively; IPSS at 8, 12, 24 and 36 months was 7 or less; 14% of patients were in preoperative retention with 94% of those patients passing their trial of voids; Secondary intervention due to recurrent LUTS was 1.6%.